Is Additional Systematic Biopsy Necessary in All Initial Prostate Biopsy Patients With Abnormal MRI?

Cheng, Xingwang; Xu, Jinshun; Chen, Yuntian; Liu, Zhenhua; Sun, Guangxi; Yang, Ling; Yao, Jin; Zeng, Hao; Song, Bin

doi:10.3389/fonc.2021.643051

Cited by 5 publications

(6 citation statements)

References 34 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, the CDR of PI-RADS5 is very high (86–88%). 29 30 In patients with had index lesion of PI-RADS 5, the CDR in target biopsy is very high; therefore, the significance of systematic biopsy might be reduced. Moreover, in patients with PI-RADS 3 index lesions, the significance of systematic biopsy would also be reduced, because the overall CDR is low inpatients with PI-RADS 3 index lesion.…”

Section: Discussionmentioning

confidence: 99%

Sextant Systematic Biopsy Versus Extended 12-Core Systematic Biopsy in Combined Biopsy for Prostate Cancer

Chung,

Song,

Kang

et al. 2024

J Korean Med Sci

View full text Add to dashboard Cite

Background This study assessed the comparative effectiveness of sextant and extended 12-core systematic biopsy within combined biopsy for the detection of prostate cancer. Methods Patients who underwent combined biopsy targeting lesions with a Prostate Imaging Reporting and Data System (PI-RADS) score of 3–5 were assessed. Two specialists performed all combined cognitive biopsies. Both specialists performed target biopsies with five or more cores. One performed sextant systematic biopsies, and the other performed extended 12-core systematic biopsies. A total of 550 patients were analyzed. Results Cases requiring systematic biopsy in combined biopsy exhibited a significant association with age ≥ 65 years (odds ratio [OR], 2.32; 95% confidence interval [CI], 1.25–4.32; P = 0.008), PI-RADS score (OR, 2.32; 95% CI, 1.25–4.32; P = 0.008), and the number of systematic biopsy cores (OR, 3.69; 95% CI, 2.11–6.44; P < 0.001). In patients with an index lesion of PI-RADS 4, an extended 12-core systematic biopsy was required (target-negative/systematic-positive or a greater Gleason score in the systematic biopsy than in the targeted biopsy) ( P < 0.001). Conclusion During combined biopsy for prostate cancer in patients with PI-RADS 3 or 5, sextant systematic biopsy should be recommended over extended 12-core systematic biopsy when an effective targeted biopsy is performed.

show abstract

Section: Discussionmentioning

confidence: 99%

Sextant Systematic Biopsy Versus Extended 12-Core Systematic Biopsy in Combined Biopsy for Prostate Cancer

Chung,

Song,

Kang

et al. 2024

J Korean Med Sci

View full text Add to dashboard Cite

show abstract

“…At present, transrectal ultrasound (TRUS)-guided core biopsy is the most frequently performed procedure [6]. However, the tumour location can be detected only in a small number of cases (≤ 30%) when TRUS is applied [7].…”

Section: Introductionmentioning

confidence: 99%

“…It is often difficult to obtain cancer tissue. This leads to a large percentage of false-negative results, which is related to consecutive biopsies and treatment [6,8].…”

Section: Introductionmentioning

confidence: 99%

In-bore MR prostate biopsy — initial experience

et al. 2022

View full text Add to dashboard Cite

Introduction:The introduction of multiparametric MRI (mpMRI) has been a breakthrough in the diagnosis of noninvasive clinically significant prostate cancer. Currently, MR-guided prostate biopsy (in-bore biopsy) is the only biopsy method that uses real-time MRI in patients with suspected prostate cancer. The aim of the study was a retrospective analysis of the correlation between MRI results and histological findings of prostate samples suspected of malignancy, which were taken during MRI-guided biopsy. Material and methods: Thirty-nine patients with 57 lesion biopsies were enrolled in the study. Patients were aged 48-84 years (mean age 67.2 ± 9.4 years). Results: Cancer was histologically confirmed in 24 lesions, including primary cancer in 14 lesions and local recurrence in 10 lesions. Cancer was not detected in the remaining lesions (n = 33). Malignancy was confirmed in 90% of lesions previously reported as PI-RADS 5. Only one Prostate Imaging and Reporting and Data System (PI-RADS 5) lesion was histologically negative (prostatitis). Cancer was detected in 50% of lesions defined as PI-RADS 4. Cancer cells were not found in any of 23 lesions defined as PI-RADS 3 (53.5%). Most of the lesions assessed as PI-RADS 3 were located in the transitional zone (n = 19). Only four PI-RADS 3 lesions were found in the peripheral zone. Large lesions or lesions feasible for cognitive TRUS biopsy were not referred for MRI biopsy, which resulted in a higher proportion of lesions assessed as PI-RADS 3. Fourteen lesions suspected of local recurrence were assessed in our study. Cancer was found in approximately 72% of the lesions. Conclusions: Performing prostate biopsy under the guidance of real-time MRI allows precise collection of material for histological examination (even from a very small lesion). As a result, both primary cancer and local recurrence after previous radiotherapy of prostate cancer can be confirmed. (Endokrynol Pol 2022; 73 (4): 712-724)

show abstract

“…MRI‐based grading (5‐point scoring system), such as the Prostate Imaging Reporting and Data System (PI‐RADS) or Likert scores, plays a major role in stratifying the superiority of targeted biopsy over SB 9,12–15 . Specifically, MRTB has shown to perform better with a greater PI‐RADS score than SB 13,14,16–18 …”

mentioning

confidence: 99%

“…9,[12][13][14][15] Specifically, MRTB has shown to perform better with a greater PI-RADS score than SB. 13,14,[16][17][18] Radiomics is a promising approach that facilitates highthroughput extraction of image features from radiographic images to characterize the underlying tumor microarchitecture and heterogeneity, which can be subtle and may not be immediately visible on routine imaging. 19 It is an important adjuvant tool of PCa detection and risk stratification.…”

mentioning

confidence: 99%

Avoiding Unnecessary Systematic Biopsy in Clinically Significant Prostate Cancer: Comparison Between MRI‐Based Radiomics Model and PI‐RADS Category

Cheng

Chen

et al. 2022

Magnetic Resonance Imaging

Self Cite

View full text Add to dashboard Cite

Background: MRI-targeted biopsy (MRTB) improves the clinically significant prostate cancer (csPCa) detection rate with fewer biopsy cores in men with suspected PCa. However, whether concurrent systematic biopsy (SB) can be avoided in patients undergoing MRTB remains unclear.Purpose: To evaluate the potential value of MRI-based radiomics models in avoiding unnecessary SB in biopsy-naïve patients. Study type: Retrospective. Population: A total of 226 patients (mean age 66.6 AE 9.02 years) with suspicion of PCa (PI-RADS score ≥ 3) and received combined cognitive MRTB with SB were retrospectively recruited and randomly divided into training (N = 180) and test (N = 46) cohorts at an 8:2 ratio. Field Strength/Sequence: A 3.0 T, biparametric MRI (bpMRI) including T2-weighted imaging (T2WI) and apparent diffusion coefficient (ADC) map. Assessment: The whole prostate gland (PG) and the index lesion (IL) were delineated. Three radiomics models of bpMRI PG , bpMRI IL , and bpMRI PG+IL were constructed, respectively, and the performance of each radiomics model was compared with that of PI-RADS assessment. Statistical Tests: The least absolute shrinkage and selection operator (LASSO) regression method was used to select texture features. The area under the curve (AUC) and decision curve analysis were used to estimate the models. Results:The bpMRI PG+IL radiomics model exhibited good discrimination, calibration, and net benefits, which would reduce the SB biopsy in 71.2% and 71.4% of men with PI-RADS ≥ 5 lesions in the training and test cohorts, respectively. Data Conclusion: A bpMRI PG+IL radiomics model may outperform PI-RADS category in help reducing unnecessary SB in biopsy-naïve patients.

show abstract

Is Additional Systematic Biopsy Necessary in All Initial Prostate Biopsy Patients With Abnormal MRI?

Cited by 5 publications

References 34 publications

Sextant Systematic Biopsy Versus Extended 12-Core Systematic Biopsy in Combined Biopsy for Prostate Cancer

Sextant Systematic Biopsy Versus Extended 12-Core Systematic Biopsy in Combined Biopsy for Prostate Cancer

In-bore MR prostate biopsy — initial experience

Avoiding Unnecessary Systematic Biopsy in Clinically Significant Prostate Cancer: Comparison Between MRI‐Based Radiomics Model and PI‐RADS Category

Contact Info

Product

Resources

About